Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US8546399 | ABBVIE INC | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
Jun, 2031
(8 years from now) | |
US10730873 | ABBVIE INC | Salts and crystalline forms of an apoptosis-inducing agent |
Nov, 2031
(8 years from now) | |
US8722657 | ABBVIE INC | Salts and crystalline forms of an apoptosis-inducing agent |
Jan, 2032
(8 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9174982 | ABBVIE INC | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
May, 2030
(7 years from now) | |
US11369599 | ABBVIE INC | Melt-extruded solid dispersions containing an apoptosis-inducing agent |
May, 2032
(9 years from now) | |
US11110087 | ABBVIE INC | Combination therapy of a type II anti-CD20 antibody with a selective Bcl-2 inhibitor |
Sep, 2033
(10 years from now) | |
US10993942 | ABBVIE INC | Combination therapy of a type II anti-CD20 antibody with a selective BCL-2 inhibitor |
Sep, 2033
(10 years from now) | |
US11413282 | ABBVIE INC | Combination therapy of a type II anti-CD20 antibody with a selective BCL-2 inhibitor |
Sep, 2033
(10 years from now) | |
US9539251 | ABBVIE INC | Combination therapy of a type II anti-CD20 antibody with a selective Bcl-2 inhibitor |
Sep, 2033
(10 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | May 15, 2026 |
M (M) | Oct 16, 2023 |
Market Authorisation Date: 11 April, 2016
Treatment: Treatment of adult patients with chronic lymphocytic leukemia (cll) or small lymphocytic lymphoma (sll); Treatment in combination with azacitidine or decitabine or low-dose cytarabine of newly-diagnosed acute myeloid leukemia (aml) in adults who are age 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy; Treatment of patients with chronic lymphocytic leukemia (cll) or small lymphocytic lymphoma (sll), with or without 17p deletion, who have received at least one prior therapy; Treatment of adult patients with chronic lymphocytic leukemia (cll) or small lymphocytic lymphoma (sll), with or without 17p deletion, who have received at least one prior therapy; Treatment of acute myeloid leukemia (aml) by orally administering venetoclax with azacitidine or decitabine or low-dose cytarabine in adults 75 years or older or having certain comorbidities according to a dose ramp-up including a 100 mg per day dose; Treatment of chronic lymphocytic leukemia (cll) or small lymphocytic lymphoma (sll) by orally administering venetoclax to an adult according to a dose ramp-up including a 100 mg per day dose; Treatment of chronic lymphocytic leukemia (cll) or small lymphocytic lymphoma (sll) by orally administering venetoclax to an adult according to a dose ramp-up that includes a dose of 50 mg per day for 1 week followed by 100 mg per day for 1 week; Treatment of adults with relapsed, refractory or previously untreated chronic lymphocytic leukemia including a dose ramp-up and in combination with obinutuzumab in multiple 28-day dosing cycles followed by administration in absence of obinutuzumab; Treatment of adult patients with chronic lymphocytic leukemia (cll) or small lymphocytic leukemia (sll) in combination with a ga101 antibody such as obinutuzumab for one or more dosing periods, wherein the cll or sll is a cd20-expressing cancer
Dosage: TABLET;ORAL
40
United States
14
Japan
13
China
13
Korea, Republic of
9
European Union
8
Russia
7
Mexico
7
Taiwan, Province of China
7
Canada
7
Israel
7
Australia
6
Singapore
6
Uruguay
5
Brazil
5
Costa Rica
5
New Zealand
5
Argentina
5
Hong Kong
5
South Africa
4
Portugal
4
Spain
4
Croatia
4
Dominican Republic
4
Peru
4
Cyprus
4
Slovenia
4
Hungary
4
Poland
4
RS
4
Denmark
3
Malaysia
3
Colombia
3
Norway
3
Lithuania
3
ME
3
Ukraine
3
Chile
3
Ecuador
2
Guatemala
2
San Marino
1
Philippines
1
Netherlands
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic